SLC10A1
Hepatic sodium/bile acid cotransporter
As of the edition of 20 October 2026, SLC10A1 (hepatic sodium/bile acid cotransporter, UniProt Q14973) has 3 drugs tested at it and 3 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14973
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 11
- Disease areas
- Digestive system; Infections; Mouth and teeth
- Registered trials of its drugs
- 28
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bulevirtide | Marketed | Phase 3 | Ends 2038 |
| Hepalatide | Active | Phase 3 | none listed |
| Myrcludex b | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Gilead Sciences | Route B |
| Hepatera | Route A |
The other 1 company at SLC10A1
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at SLC10A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.